Skip to main content
Premium Trial:

Request an Annual Quote

George Rathmann Dies

George Rathmann, Amgen's founding chief executive, has died, reports The New York Times. He was 84. Rathmann led Amgen in the 1980s while it developed what the Times calls "two of the most successful drugs in history" — Epogen and Neupogen. "He was the one who created the company, without any doubt," says Lowell Sears, a former chief financial officer at Amgen.

"Rathmann is widely considered one of the fathers of the biotechnology industry," the Times adds.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.